Medical News

RSS

Xeomin receives FDA approval for treatment of cervical dystonia

Merz Pharmaceuticals today announced that the United States Food and Drug Administration has approved Xeomin (incobotulinumtoxinA), a botulinum toxin type A for the treatment of adults with cervical dystonia or blepharospasm. According to an epidemiology study conducted in Rochester, Minnesota, the prevalence of focal dystonia, which includes cervical dystonia and blepharospasm, is estimated at 295 per million people in the U.S.

2 Aug 2010

Explorys secures $2.55M Series B financing from Santé Ventures

Explorys Inc., the leader in cloud computing solutions for healthcare data management, analytics, and outcomes measurement has secured $2.55M Series B financing from Santé Ventures, with follow-on participation from Cleveland Clinic Innovations.

2 Aug 2010

Cannabis Medical Solutions signs merchant services agreements with four medical marijuana dispensaries

Cannabis Medical Solutions Inc., a leading company specializing in both brick-and-mortar and online merchant payment solutions and financial security products for medical marijuana dispensaries and high-risk merchant accounts, today announced that the Company has signed merchant services agreements with four additional medical marijuana dispensaries located in California and Colorado. Under the new agreements, CMSI will provide merchant services, cash advance POS systems and The MediPayment closed loop patient system to the licensed dispensaries.

2 Aug 2010

BD announces sale of surgical blades product platform, Ophthalmic Systems unit

BD, a leading global medical technology company, today announced the completion of the sale of its Ophthalmic Systems unit to RoundTable Healthcare Partners and the sale of its surgical blades product platform to one of RoundTable's portfolio companies, Aspen Surgical Products, Inc.

From BD (Becton, Dickinson and Company) 2 Aug 2010

Verizon Business to help courts, prison health care systems with new technology solutions

Courts grappling with jammed dockets and prisons struggling to handle inmate health care issues can now put the power of video collaboration to work, with a new, tailored set of technology solutions and professional consulting services from Verizon Business.

2 Aug 2010

Highmark Caring Place announces launch of enhanced website to assist families in need

The Highmark Caring Place has served more than 60,000 grieving families and community members since the first location opened in Pittsburgh in 1997. Since then, additional facilities have opened in Erie, Lemoyne and Warrendale, Pa. To further extend the reach of the facility-based support services available to children and families in need, the Caring Place has launched a redesigned website to assist families in need who are unable to participate in onsite activities.

2 Aug 2010

Phase I/II clinical study data of OncoVEXGM-CSF for head and neck cancer published in Clinical Cancer Research

BioVex Inc, a company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announces that the data from its completed Phase I/II clinical study of OncoVEXGM-CSF for the first line treatment of head and neck cancer is being published today in Clinical Cancer Research, an ASCO publication.

2 Aug 2010

Teleflex receives forty-one approvals for certificates to foreign governments from FDA

Teleflex Incorporated today announced that it has received approval of a significant number of additional certificates to foreign governments ("CFG") from the FDA, totaling forty-one approvals out of eighty-five submitted requests.

2 Aug 2010

Study: hGH linked to PROLOR's CTP technology increases half-life, bioactivity

PROLOR Biotech, Inc., a company developing next generation biobetter therapeutic proteins, today reported publication of a preclinical study in the current on-line edition of the journal Endocrinology showing that human growth hormone (hGH) linked to PROLOR's carboxyl terminal peptide (CTP) technology has significantly increased half-life and bioactivity compared to commercially available hGH. The publication, which is authored by PROLOR researchers, will also be included in the September print edition of Endocrinology.

2 Aug 2010

Aradigm closes private placement with Novo Nordisk

Aradigm Corporation today announced that it has entered into a Stock Purchase Agreement providing for the issuance by the Company of 26 million shares of the Company's common stock to Novo Nordisk A/S in a private placement as consideration for the termination of a promissory note in favor of Novo Nordisk under which approximately $9.1 million is currently outstanding, representing an effective price per share of $0.3505.

2 Aug 2010

Henry Schein second-quarter 2010 net sales increase 15.1% to $1.8 billion

Henry Schein, Inc., the largest provider of healthcare products and services to office-based practitioners, today reported record financial results for the quarter ended June 26, 2010.

2 Aug 2010

HDL does not predict heart attack risk after dramatic statin therapy: Study

People with high levels of "good cholesterol," HDL-C, tend to have fewer heart attacks, but HDL-C may offer little protection to people who take statins to lower harmful LDL cholesterol, researchers reported July 21. At Brigham and Women's Hospital in Boston, Dr. Paul Ridker and colleagues analyzed a large study of healthy people who took the statin CRESTOR® (rosuvastatin calcium) to prevent heart attacks. They found that in this group, having high HDL-C was a bad predictor of heart attack risk.

2 Aug 2010

Rethink Autism, eSchool News offer webinar to show how schools can save costs using new technology

Public school administrators are facing the prospect of deeper budget cuts in cities and states nationwide. Meanwhile, schools with fewer resources are challenged to comply with the federal Individuals with Disabilities Education Act, which guarantees "free appropriate" education to all disabled students, including the growing number of students with an Autism Spectrum Disorder. In addition, parents are pressuring schools to either comply with the IDEA or face legal action.

2 Aug 2010

K-V Pharmaceutical receives NYSE non-compliance notification

K-V Pharmaceutical Company announced today that the Company received notification from the New York Stock Exchange on July 27, 2010 of non-compliance regarding the Company's quantitative continued listing standards. The NYSE informed the Company that its Class A Common Stock equity issue has fallen below criteria for the average closing price of a NYSE security of not less than $1.00 over a consecutive 30-trading day period.

2 Aug 2010

Life Technologies launches new assay to detect deadly strain of E. coli

Life Technologies, a provider of innovative life science solutions, announced at the International Association of Food Protection annual meeting the launch of the MicroSEQ E. coli O157:H7 assay, designed to detect the deadly strain of Escherichia coli (E. coli), using the company's industry-leading real-time PCR technology.

2 Aug 2010

DAIICHI SANKYO EUROPE adopts DATATRAK's eClinical platform for cardiovascular clinical study

DATATRAK International, Inc., a technology and services company focused on global eClinical solutions for the clinical trials industry, today announced that DAIICHI SANKYO EUROPE GmbH has selected DATATRAK's eClinical™ platform for a cardiovascular clinical study encompassing 80 sites and 1,200 patients across Europe.

2 Aug 2010

Trimega Laboratories CEO shortlisted for 'Entrepreneur of the Year' in National Business Awards

Avi Lasarow, CEO of Trimega Laboratories, has been shortlisted for 'Entrepreneur of the Year' in the National Business Awards for the second year running.

2 Aug 2010

LifePoint Hospitals second-quarter revenues up 7.5% to $790.6 million

LifePoint Hospitals, Inc. today announced results for the second quarter and six months ended June 30, 2010.

2 Aug 2010

Charles River Laboratories International second-quarter 2010 net sales decline 5.2%

Charles River Laboratories International, Inc. today reported its results for the second quarter of 2010. For the quarter, net sales were $292.1 million, a decline of 5.2% from $308.2 million in the second quarter of 2009. Foreign currency translation reduced the sales growth rate by 0.1%. A modest sales increase in the Research Models and Services segment was offset by lower sales for the Preclinical Services segment.

2 Aug 2010

First Edition: August 2, 2010

Today's headlines include news about a pre-recess Senate push to pass a state aid measure as well as a preview of a White House report to be issued today that predicts savings in the Medicare program.

2 Aug 2010

Medical News

Xeomin receives FDA approval for treatment of cervical dystonia

Explorys secures $2.55M Series B financing from Santé Ventures

Cannabis Medical Solutions signs merchant services agreements with four medical marijuana dispensaries

BD announces sale of surgical blades product platform, Ophthalmic Systems unit

Verizon Business to help courts, prison health care systems with new technology solutions

Highmark Caring Place announces launch of enhanced website to assist families in need

Phase I/II clinical study data of OncoVEXGM-CSF for head and neck cancer published in Clinical Cancer Research

Teleflex receives forty-one approvals for certificates to foreign governments from FDA

Study: hGH linked to PROLOR's CTP technology increases half-life, bioactivity

Aradigm closes private placement with Novo Nordisk

Henry Schein second-quarter 2010 net sales increase 15.1% to $1.8 billion

HDL does not predict heart attack risk after dramatic statin therapy: Study

Rethink Autism, eSchool News offer webinar to show how schools can save costs using new technology

K-V Pharmaceutical receives NYSE non-compliance notification

Life Technologies launches new assay to detect deadly strain of E. coli

DAIICHI SANKYO EUROPE adopts DATATRAK's eClinical platform for cardiovascular clinical study

Trimega Laboratories CEO shortlisted for 'Entrepreneur of the Year' in National Business Awards

LifePoint Hospitals second-quarter revenues up 7.5% to $790.6 million

Charles River Laboratories International second-quarter 2010 net sales decline 5.2%

First Edition: August 2, 2010

Exploring the nanoscale: How AFM is transforming cosmetic science

Innovating Texture and Culture in Plant-Based Foods

Advancing brain microphysiological systems (bMPS)

Latest News